Related Experiment Video
Updated: Aug 7, 2026
Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage: A Placebo-Controlled Trial
Aristeidis H Katsanos1,2, Kelvin K H Ng1, Thalia S Field3
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada (A.H.K., K.K.H.N., A. Srivastava, A. Shoamanesh).
Insights
Testing low-dose colchicine after acute intracerebral hemorrhage (ICH) is feasible. Future trials should address early study drug discontinuation in this patient population to improve outcomes.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Intracerebral hemorrhage (ICH) survivors face risks of major adverse cardiovascular events and secondary brain injury.
- Novel treatments are needed to mitigate these post-ICH complications.
Purpose of the Study:
- To determine the feasibility of testing colchicine in patients with acute intracerebral hemorrhage (ICH).
- To assess recruitment rates, participant retention, and medication adherence in a pilot randomized clinical trial.
Main Methods:
- A double-blind, placebo-controlled pilot randomized clinical trial was conducted across 11 Canadian centers.
- Adults within 48 hours of ICH onset were randomized to oral colchicine (0.5 mg daily) or placebo.
- Feasibility outcomes included recruitment rate, 6-month retention, and 12-month medication adherence.
Main Results:
- The study recruited 100 participants (52 colchicine, 48 placebo) with an average recruitment rate of 8.9 participants/site/year.
- Six-month retention was 92%, and 12-month medication adherence was 97% among those not discontinuing the drug.
- No significant differences in exploratory efficacy or safety endpoints were observed between groups.
Conclusions:
- It is feasible to conduct clinical trials testing low-dose colchicine in acute intracerebral hemorrhage (ICH) patients.
- Future research should consider strategies to manage high rates of early permanent study drug discontinuation in this population.
Background:
There is a need for novel treatments that lower the risk of major adverse cardiovascular events and secondary inflammatory brain injury after an intracerebral hemorrhage (ICH).
Methods:
We performed a double-blind, placebo-controlled, pilot randomized clinical trial at 11 centers across Canada to determine the feasibility of testing colchicine after an acute ICH. We recruited adults presenting within 48 hours of ICH onset with vascular neuroimaging evidence or risk factors for atherosclerosis. Participants were randomized to oral colchicine 0.5 mg daily or placebo and followed to a common study termination date. The primary feasibility outcome was the recruitment rate (participants/center per year). Secondary feasibility outcomes included retention of participants at 6 months and medication adherence at 12 months. This trial is registered (URL: https://www.clinicaltrials.gov; Unique identifier: NCT05159219).
Results:
Between August 2022 and March 2024, 52 participants were allocated to colchicine 0.5 mg daily and 48 participants to placebo daily. Participants were, on average, 68 years old, and 60% were male. The mean time from ICH onset to randomization was 35 hours. The average recruitment rate was 8.9 participants/site per year. Retention at 6 months was 92% (colchicine 91% versus placebo 93%). Following randomization, 14 participants (27%) in the colchicine group and 13 participants (27%) in the placebo group permanently discontinued the study drug. Excluding participants who died or permanently discontinued the study intervention, 12-month medication adherence was 97%, with similar rates between the colchicine and placebo groups (100% versus 93%). We detected no difference in predefined exploratory efficacy or safety end points between the 2 groups over the median follow-up time of 364 days.
Conclusions:
It is feasible to test low-dose colchicine after an acute ICH. Future randomized clinical trials should account for the high rates of early permanent study drug discontinuation in this patient population.
Registration:
URL: https://www.clinicaltrials.gov; Unique identifier: NCT05159219.
